Unknown

Dataset Information

0

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT.

ABSTRACT:

SUBMITTER: Redjoul R 

PROVIDER: S-EPMC8415894 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Antibody response after second BNT162b2 dose in allogeneic HSCT recipients.
| S-EPMC8277189 | biostudies-literature
Unknown Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients.
| S-EPMC8489274 | biostudies-literature
Unknown Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience.
| S-EPMC8397500 | biostudies-literature
Unknown BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response.
| S-EPMC8058049 | biostudies-literature
Unknown SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis.
| S-EPMC8425695 | biostudies-literature
Unknown Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients.
| S-EPMC4472330 | biostudies-literature
Unknown Severe acute respiratory syndrome coronavirus 2 antibody response to a third dose of homologous messenger RNA vaccination in liver transplantation recipients.
| S-EPMC9088577 | biostudies-literature
Unknown The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients.
| S-EPMC8853982 | biostudies-literature
Unknown Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients.
| S-EPMC7686902 | biostudies-literature
Unknown Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT.
| S-EPMC4880046 | biostudies-literature